Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
After one patient death prompted an FDA hold this spring, Newron Pharmaceuticals has now shared that a total of four fatalities have been recorded among participants receiving its schizophrenia candidate. A fifth death was recorded among those taking the placebo.
Original title: “Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold”
For the second time in a week, Zealand Pharma’s weight loss pipeline has delivered mixed results, this time in a Phase 2 trial for the Roche-partnered asset petrelintide.
Original title: “Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers”
Company expands pipeline into car‑t and genetic medicine
Original title: “Laverock unveils new in vivo programmes in oncology”
Early findings support phase 2 plans for 2027
Original title: “Atrogi reports human data showing muscle gains with ATR‑258”
Call aims to support research preventing deadly newborn infections
Original title: “Group B Strep mums urge women to join vaccine trial”
In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well.
Original title: “Beyond equity: Why venture debt is reshaping European biotech”
Big Pharma companies including Bristol Myers Squibb, Johnson & Johnson and Novartis are among those that made or planned layoffs in Q3. Those cuts could affect over 1,800 employees, with New Jersey the hardest-hit state.
Original title: “Q3 layoffs down YOY, with 90% fewer biopharma employees affected”
oral deucrictibant for on demand treatment of hereditary angioedema attacks a phase 3 multicentre randomised double blind placebo controlled crossover trial
Original title: “Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.”